Patents by Inventor Lance E. Steward

Lance E. Steward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MICRONEEDLE ARRAY WITH ACTIVE INGREDIENT
    Publication number: 20240050726
    Abstract: Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles comprises at least one dissolvable polymer. The active ingredient is incorporated in the elongate body, and the active ingredient is present only in the distal portion and at least internally in the distal portion.
    Type: Application
    Filed: March 19, 2023
    Publication date: February 15, 2024
    Applicant: Allergan, Inc.
    Inventors: Futian LIU, Xiaojie YU, Lance E. STEWARD, Guang Wei LU, Patrick M. HUGHES, Seshadri NEERVANNAN
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20240018500
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: September 23, 2022
    Publication date: January 18, 2024
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Femandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Botulinum Neurotoxin Proteins and Methods to Engineer and Generate Same
    Publication number: 20230332126
    Abstract: Botulinum neurotoxin proteins and fragments thereof that bind and/or cleave a noncanonical substrate, e.g., non-neuronal SNARE proteins such as human SNAP-23 (hSNAP-23) and SNAP-29 (hSNAP-29), are described.
    Type: Application
    Filed: August 24, 2021
    Publication date: October 19, 2023
    Inventors: Gregory A. Weiss, Amy D. Brideau-Andersen, Rebekah P. Dyer, Lance E. Steward, Linh Q. Le, Gaetano Speciale, David C. Rupp, Birgitte P.S. Jacky, Madison H. Fletcher, Sudipta Majumdar
  • MICRONEEDLE ARRAY WITH ACTIVE INGREDIENT
    Publication number: 20230321420
    Abstract: Microneedle arrays for introducing an active ingredient through a skin surface of a patient can include a base layer, a plurality of microneedles projecting from the base layer, and a shell layer having an active ingredient. Each of the microneedles includes an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles can also include at least one dissolvable polymer. The active ingredient is incorporated in the shell layer, which extends around at least a portion of the elongate body.
    Type: Application
    Filed: December 14, 2022
    Publication date: October 12, 2023
    Applicant: Allergan, Inc.
    Inventors: Futian LIU, Xiaojie YU, Lance E. STEWARD
  • BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN
    Publication number: 20230302103
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Application
    Filed: December 21, 2022
    Publication date: September 28, 2023
    Inventors: Birgitte P.S. Jacky, Shizazh Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsia
  • MICRONEEDLE ARRAY WITH ACTIVE INGREDIENT
    Publication number: 20220008702
    Abstract: Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles comprises at least one dissolvable polymer. The active ingredient is incorporated in the elongate body, and the active ingredient is present only in the distal portion and at least internally in the distal portion.
    Type: Application
    Filed: July 19, 2021
    Publication date: January 13, 2022
    Inventors: Futian LIU, Xiaojie YU, Lance E. STEWARD, Guang Wei LU, Patrick M. HUGHES, Sheshadri NEERVANNAN
  • Microneedle array with active ingredient
    Patent number: 11065428
    Abstract: Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles comprises at least one dissolvable polymer. The active ingredient is incorporated in the elongate body, and the active ingredient is present only in the distal portion and at least internally in the distal portion.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: July 20, 2021
    Assignee: Allergan, Inc.
    Inventors: Futian Liu, Xiaojie Yu, Lance E. Steward, Guang Wei Lu, Patrick M. Hughes, Sheshadri Neervannan
  • BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN
    Publication number: 20210162027
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Application
    Filed: February 3, 2021
    Publication date: June 3, 2021
    Inventors: Birgitte P.S. Jacky, Shizazh Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsia
  • Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
    Patent number: 10912823
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: February 9, 2021
    Assignee: Allergan, Inc.
    Inventors: Birgitte P.S. Jacky, Shiazah Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20200190496
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 18, 2020
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • MICRONEEDLE ARRAY WITH ACTIVE INGREDIENT
    Publication number: 20200054869
    Abstract: Microneedle arrays for introducing an active ingredient through a skin surface of a patient can include a base layer, a plurality of microneedles projecting from the base layer, and a shell layer having an active ingredient. Each of the microneedles includes an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles can also include at least one dissolvable polymer. The active ingredient is incorporated in the shell layer, which extends around at least a portion of the elongate body.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 20, 2020
    Inventors: Futian LIU, Xiaojie YU, Lance E. STEWARD
  • Degradable clostridial toxins
    Patent number: 10501731
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 10, 2019
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • BOTULINUM NEUROTOXIN FOR TREATMENT OF DISORDERS ASSOCIATED WITH MELANOCYTE HYPERACTIVITY AND/OR EXCESS MELANIN
    Publication number: 20180344820
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Birgitte P.S. Jacky, Shizazh Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
  • Microneedle array with active ingredient
    Publication number: 20180236215
    Abstract: Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles comprises at least one dissolvable polymer. The active ingredient is incorporated in the elongate body, and the active ingredient is present only in the distal portion and at least internally in the distal portion.
    Type: Application
    Filed: February 16, 2018
    Publication date: August 23, 2018
    Inventors: Futian LIU, Xiaojie YU, Lance E. STEWARD, Guang Wei LU, Patrick M. HUGHES, Sheshadri NEERVANNAN
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20180119126
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: December 18, 2017
    Publication date: May 3, 2018
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Methods of intracellular conversion of single-chain proteins into their di-chain form
    Patent number: 9938514
    Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: April 10, 2018
    Assignee: Allergan, Inc.
    Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
  • Degradable clostridial toxins
    Patent number: 9850476
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: December 26, 2017
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Methods Of Intracellular Conversion Of Single-Chain Proteins Into Their Di-Chain Form
    Publication number: 20160319265
    Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.
    Type: Application
    Filed: May 16, 2016
    Publication date: November 3, 2016
    Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20160201046
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: March 28, 2016
    Publication date: July 14, 2016
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Methods of intracellular conversion of single-chain proteins into their di-chain form
    Patent number: 9340813
    Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: May 17, 2016
    Assignee: Allergan, Inc.
    Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward